Investment
Features
FeesSafety
Academy
More
Pluang+

Park Avenue Securities cuts stake in Vertex Pharmaceuticals by 8.2% in Q4, insiders also sold shares recently.

Market News
22 Mar 2026
Defense World
View Source
Bearish
pluang ai news

Park Avenue Securities LLC reduced its holdings in Vertex Pharmaceuticals by 8.2% in the fourth quarter, selling 1,236 shares and holding 13,807 shares valued at $6.26 million. Several other institutional investors slightly increased their stakes. Meanwhile, Vertex insiders, including the CMO and EVP, sold shares worth millions, reducing their ownership by over 6%. Despite these sales, Vertex reported solid quarterly earnings with revenue up 9.5% year-over-year and maintains a strong market position with a consensus analyst rating of Moderate Buy and an average price target of $554.30.

More News (VRTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App